Triana adds $120m to push its glue programme

Triana Biomedicines, a company developing oncology molecular glue degraders, has secured a $120m series B financing round with Pfizer, once again, among its investors. Pfizer had previously backed Triana’s $110m series A, and has already locked in a collaboration for the development of molecular glue degraders in several disease areas. Under that deal Pfizer paid $49m up front. Triana’s raise comes amid a broader surge of interest in degrader medicines: Roche, AbbVie, Lilly and Gilead have all invested in this area in 2025. Triana plans to use the new financing to bring its lead asset, the ALK degrader TRI-611, into the clinic. The project could increase pressure on other companies in the ALK space such as Nuvalent, whose fourth-generation ALK inhibitor neladalkib recently yielded updated results from the Alkove-1 study evaluating it in ALK-mutated non-small cell lung cancer. These data will be taken to regulators, but the update also came with news of the need for enhanced monitoring owing to liver enzyme elevations. Beyond TRI-611 Triana intends to continue progressing its pipeline, which includes breast and colorectal cancer programmes in early development.

Triana Biomedicines' pipeline 

Source: OncologyPipeline & Triana Biomedicines' website.